{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-038977","form_type":"8-K","ticker":"ABSI","cik":"0001672688","company_name":"Absci Corp","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.012550+00:00","generated_at":"2026-06-08T03:43:11.451367+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Absci partners with Almirall (up to $664M deal) and reports Q3 net loss of $22M","bullets":["Entered AI drug partnership with Almirall for dermatology; up to $664M in milestones plus royalties for two programs.","Q3 revenue fell to $0.7M from $2.4M YoY; net loss narrowed to $22.0M from $27.3M.","Unveiled four wholly-owned AI drug assets (cytokine biology); first IND filing expected early 2025.","Cash, equivalents, and short-term investments $113.5M; cash runway into late 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-038977","json":"https://secwatch.observer/filing/0001628280-23-038977.json","markdown":"https://secwatch.observer/filing/0001628280-23-038977.md","text":"https://secwatch.observer/filing/0001628280-23-038977.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672688/000162828023038977/0001628280-23-038977-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672688/000162828023038977/absc-20231114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:43:11.451367+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"086265df87bd80a073c3596027d42a8bbfb1211b","claim":"Absci Corp reported the quarter ended September 30, 2023 results: revenue $0.7 million, net income Net loss was $22.0 million.","evidence_excerpt":"Revenue was $0.7 million for the three months ended September 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1672688/000162828023038977/0001628280-23-038977-index.htm","confidence":0.97,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Revenue","value":"$0.7 million"},{"label":"Net income","value":"Net loss was $22.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}